Skip to main content


Full Year 2019 Audited Financial Results

12 March 2020

Productive year with robust results and further reduction in net debt.

London – 12 March 2020 – Urenco Group (“Urenco” or “the Group”), an international supplier of uranium enrichment services and nuclear fuel cycle products, today announces its results for the full year ended 31 December 2019.

  • Strong operating cash flow generation of €1,094.3 million, with continued reduction of net financial debt to €928.1 million (32.3% reduction year-on-year), down from €2.8 billion at the end of 2015.
  • Revenue of €1,804.5 million (down 7.8% year-on-year).
  • EBITDA of €1,219.6 million (in line with 2018), driven by our current order book and strong operational performance.
  • Net income of €7.6 million impacted by exceptional items due to impairment of USA operations (€446.0 million post-tax) and increase in nuclear provisions as a result of lower discount rates (€111.2 million post-tax).

Financial Highlights (€m)

  2019 2018
Revenue 1,804.5 1,957.7
EBITDA (i) 1,219.6 1,200.4
EBITDA margin % 67.6% 61.3%
Income from operating activities (pre-exceptional items) 850.2 826.5
Exceptional items (pre-tax) (ii) (643.0) -
Income from operating activities (post-exceptional items) 207.2 826.5
Net income (pre-exceptional items) 564.8 511.3
Exceptional items (post-tax) (ii) (557.2) -
Net income (post-exceptional items) 7.6 511.3
Earnings per share (post-exceptional items) 0.1 3.0
Capital expenditure (iii) 151.4 183.1
Cash generated from operating activities 1,094.3 1,401.0

(i) EBITDA is earnings before exceptional items, interest (including other finance costs), taxation, depreciation and amortisation and joint venture results. Depreciation and amortisation are adjusted to remove elements of such charges included in changes to inventories and net costs of nuclear provisions. Further details on the calculation of EBITDA are set out in note 4 to the Group’s Consolidated Financial Statements contained in the 2019 Annual Report and Accounts.

(ii) Exceptional items comprise impairment of USA operations (€500.0 million pre-tax, €446.0 million post-tax) and increase in nuclear provisions as a result of lower discount rates (€143.0 million pre-tax, €111.2 million post-tax).

(iii) Capital expenditure includes net cash flows from investing activities (excluding interest received) and capital accruals (included in working capital payables).

Boris Schucht, Chief Executive of Urenco Group, commenting on the full year results, said:

“2019 was a productive year. We accepted new business at levels which will enable us to reinvest in our enrichment facilities and reduced our net financial debt to its lowest level since it peaked in 2015. Our revenue, EBITDA and net income before exceptional items all remained robust. We once again met 100% of our customer deliveries while providing a record volume of enrichment services.

We continue to experience challenges in the enrichment market. As a result of this, we recorded an impairment against the carrying value of our US operations in 2019 of €446 million (post tax) due to the market being forecast to recover more slowly than previously predicted. However, there is scope for optimism, as the spot enrichment price has recovered by 38%, reaching US$47/SWU by the end of October 2019 from its lowest point of US$34/SWU in August 2018.

Our four-year strategy concluded at the end of 2019, with the achievements including more than €300 million in cumulative cash savings and efficiencies, a redefined commercial strategy and an extended customer order book. We are refreshing our strategy and launching a new organisational culture project, which we are confident will further secure our long-term future.

An exciting milestone in 2019 was the completed construction of our €1 billion state-of-the-art Tails Management Facility in the UK. Active commissioning of the TMF is ongoing and, when operational, it will help Urenco responsibly manage the by-product of our enrichment services. Another significant investment, the extension of our Stable Isotopes facility in the Netherlands, will be opened in 2020. This will enable us to enrich non-uranic elements which are used in scientific and medical applications, including the treatment of serious illnesses.

In 2020 we are celebrating 50 years of successful operation. We have our sights set firmly on the next 50 years. We are proud to continue to serve the nuclear industry, making a key contribution to sustainable energy generation in a low-carbon world.”

Financial Results

Revenue for the year ended 31 December 2019 was €1,804.5 million, a decrease of 7.8% on the €1,957.7 million in 2018. Both SWU revenues and uranium related sales were lower in 2019 by €53.5 million and €74.6 million respectively. For SWU revenues, volumes were slightly higher than the previous year but with lower average unit revenues. By contrast, uranium related sales experienced significantly lower volumes but with higher realised unit prices. Other revenues decreased by €25.1 million compared to 2018, primarily as a result of lower sales at Urenco Nuclear Stewardship and losses associated with uranium related commodity contracts.

EBITDA for 2019 was €1,219.6 million, an increase of €19.2 million (1.6%) from €1,200.4 million in 2018, corresponding to an EBITDA margin of 67.6% for 2019 (2018: 61.3% in 2018), with the EBITDA margin in 2018 being adversely impacted by the triennial review of nuclear liabilities carried out in that year.

EBITDA for 2019 reflects the different mix in customer deliveries between the two years satisfied from in-year production and inventories (2019: €(5.5) million, 2018: €(146.5) million). In 2019 EBITDA also benefited from lower net costs of nuclear provisions (€19.4 million) and lower other operating and administrative expenses (€12.0 million).

The net costs of nuclear provisions (before exceptional items) were €154.7 million in 2019 compared to €174.1 million in 2018, a decrease of €19.4 million. The net costs for tails provisions in 2019 were €8.2 million more than those for 2018. The net costs for decommissioning provisions in 2019 decreased by €66.8 million primarily due to a lower charge for additional provisions of €nil million (2018: €65.9 million), with 2018 reflecting the triennial review of nuclear liabilities, together with a slightly higher release of provisions in the year of €9.7 million (2018: €8.8 million) associated with cylinder assets. The net costs for other nuclear provisions in 2019 increased by €39.2 million primarily as a result of changes to the forecasts for future re-enrichment of low assay feed.

Other operating and administrative expenses were €424.7 million in 2019 compared to €436.7 million in 2018, a decrease of €12.0 million.

Exceptional items totalling €643.0 million on a pre-tax basis (€557.2 million post-tax) were reported in 2019 (2018: €nil). The total net income tax credit associated with the exceptional items was €85.8 million (2018: €nil).

The majority of the charge relates to an impairment of the carrying value of the US operations of €500.0 million (€446.0 million post-tax), as a result of further downward pressure on long-term price forecasts for uncontracted SWU volumes, compared with those assumed at the time of the construction of the US operations and also since the impairment charge recorded in 2016. These pressures are due to a combination of factors, including premature closure of nuclear reactors due to economic reasons, primarily in unregulated markets, excess capacity in global enrichment and the build-up of surplus inventories.

In addition, an exceptional charge of €143.0 million on a pre-tax basis (€111.2 million post-tax) arose due to the increase in the value of nuclear provisions held by the European enrichment businesses following a revision to the discount rates applied to the provisions due to continued downward pressure on real interest rates in Europe. Of the €143.0 million, €111.3 million relates to tails provisions and €31.7 million relates to decommissioning provisions.

Depreciation and amortisation for 2019 was €356.2 million (2018: €329.2 million), with the higher charge in 2019 reflecting adverse impacts from movements in foreign exchange rates in addition to an increase in the depreciation of decommissioning assets following the triennial review carried out in 2018.

Income from operating activities post-exceptional items was €207.2 million (2018: €826.5 million) and Income from operating activities pre-exceptional items was €850.2 million (2018: €826.5 million).

Net finance costs for 2019 were €107.1 million, compared to €106.0 million for 2018. The net finance costs on borrowings (including the impact of interest rate/cross currency interest rate swaps) were €5.8 million higher at €81.1 million, reflecting the €9.9 million of costs associated with the repurchase and cancellation of €215.6 million of February 2021 Eurobonds. Underlying net finance costs were lower reflecting the lower levels of net debt in 2019, although this is partially offset by the lower levels of interest income on cash balances.

In 2019 the pre-exceptional tax expense was €178.3 million (an effective tax rate (ETR) of 24.0%), a decrease of €30.9 million over the tax expense of €209.2 million for 2018 (ETR: 29.0%). The decrease in the ETR arose primarily from the impact of non-taxable and non-deductible amounts, including foreign exchange financing gains and losses that are excluded from tax under the UK Disregard Regulations.

The post-exceptional tax expense of €92.5 million reflects the pre-exceptional expense of €178.3 million after the benefit of the €85.8 million net credit associated with the exceptional items.

Net income after exceptional items was €7.6 million in 2019 (2018: €511.3 million).

Net income before exceptional items was €564.8 million in 2019, an increase of €53.5 million (10.5%) compared to the 2018 net income of €511.3 million. The net income margin before exceptional items for 2019 was 31.3% compared to 26.1% for 2018.

Operating cash flow before movements in working capital was €1,288.3 million (2018: €1,293.8 million) and cash generated from operating activities was €1,094.3 million (2017: €1,401.0 million). The lower cash flows from operating activities primarily result from lower revenues and adverse movements in working capital compared to 2018.

Tax paid in the period was €141.5 million (2018: €119.3 million) due to the timing and phasing of cash payments which can often span multiple years.

In 2019 Group capital expenditure (iiii) was €151.4 million (2018: €183.1 million), reflecting a lower level of expenditure on both core enrichment assets and the TMF (2019: €43.0 million, 2018: €76.0 million). Expenditure on core enrichment assets is now broadly at a level forecast as part of our strategy and appropriate to maintain the existing fleet of enrichment asset for the near to mid-term. Completion of construction of the TMF was achieved in late 2018 and active commissioning is ongoing.

Net cash outflow from financing activities was €1,101.8 million (2018: €681.8 million) which includes the placement of €464.1 million in short term deposits, the majority of which mature in March 2020. In 2019 the Group repurchased and cancelled €215.6 million of the February 2021 Eurobonds for a price of €225.5 million (104.6%). The transaction was completed in January 2019 for a total amount of €230.5 million, which included €5.0 million of accrued interest on these Eurobonds. As at 31 December 2019, a nominal amount of €534.4 million remained outstanding on the February 2021 Eurobonds. In March 2019, €300.0 million in dividends for the year ended 31 December 2018 were paid to shareholders (2018: €300.0 million).

As at 31 December 2019, the Group held short-term deposits and cash and cash equivalents of €787.3 million (31 December 2018: €531.2 million). Net debt decreased to €928.1 million (2018: €1,370.9 million) including lease liabilities of €22.0m (2018: €nil).  The Group’s debt is rated by Moody’s (Baa1/Stable) and Standard & Poor’s (BBB+/Stable); these external ratings were unchanged during 2019.

Total provisions as at 31 December 2019 were €2,187.0 million (2018: €1,776.5 million) of which €9.2 million (2018: €7.5 million) was included in current liabilities. In 2019, additional provisions and the unwinding of discounts were €612.2 million (including the impact of the change in discount rates), while utilisation and release of provisions (including exchange differences) were €201.7 million. Nuclear liabilities and the associated provisions, together with underlying macro-economic assumptions and the required funding capability, are kept under constant review by Urenco.

(iiii) Capital expenditure of €151.4 million includes net cash flows from investing activities (excluding interest received) of €145.3 million and capital accruals of €6.1 million (included in working capital payables).

Order Book

Our order book extends to the 2030s with a value as at 31 December 2019 of €10.6 billion based on €/$ of 1 : 1.12 (31 December 2018: approximately €11.9 billion based on €/$ of 1 : 1.15), providing visibility and financial stability of future revenues.


Uranium enrichment is the heart of our business, complemented by services which benefit our customers and utilise our technology and core expertise. We continue to explore growing markets: in enrichment services through our new representative office in China; in Stable Isotopes through our extended facility in the Netherlands; and in nuclear stewardship through our two UK subsidiaries dedicated to this area, Urenco Nuclear Stewardship Limited and Urenco ChemPlants Limited.

The principal risks and uncertainties to which Urenco is exposed remain broadly in line with those disclosed in 2018. Our contract order book leaves us well-placed to meet challenges from the enrichment market. We have accepted new business at levels which give us optimism that customers understand the importance of having a market that can promote reinvestment. Enriched uranium inventories have led to excess capacity in the market, and we forecast they will further decrease in the mid-term.

Policy decisions in some European countries and North America support the nuclear industry, with investment in current reactors and delays to phase-outs of capacity. Investment in new nuclear is most pronounced in Asia, where the industry is growing rapidly. Our broad offering, and the large geographic reach of our four facilities, enables us to meet this demand and make a strong contribution to the need for sustainable energy globally to meet climate change goals.

We are also continuously monitoring and mitigating geopolitical challenges. Our sites are prepared for the UK’s full withdrawal from the European Union and Euratom. We are confident we will continue to meet our global customer commitments and remain a long-term supportive partner to the nuclear industry.


Boris Schucht, Chief Executive, joined Urenco in May 2019, replacing Thomas Haeberle.  


Click here to view the full press release as a PDF.


About Urenco

Urenco is an international supplier of enrichment services and fuel cycle products with sustainability at the core of its business. Operating in a pivotal area of the nuclear fuel supply chain for 50 years, Urenco facilitates zero carbon electricity generation for consumers around the world.

With its head office near London, UK, Urenco’s global presence ensures diversity and security of supply for customers through enrichment facilities in Germany, the Netherlands, the UK and the USA. Using centrifuge technology designed and developed by Urenco, and through the expertise of our people, the Urenco Group provides safe, cost effective and reliable services; operating within a framework of high environmental, social and governance standards, complementing international safeguards.

Urenco is committed to continued investment in the responsible management of nuclear materials; innovation activities with clear sustainability benefits, such as nuclear medicine, industrial efficiency and research; and nurturing the next generation of scientists and engineers.


Sign up to our newsletter by entering your email address below.

Back to
the goals